You are a liar, Nektar Therapeutics (NASDAQ:NKTR) was downgraded from Buy to Neutral at MKM Partners. They have a PT of $13.00
On 19 November 2013, the Company announced that the US FDA acknowledged receipt of the NDA for its
investigational drug naloxegol, an oral peripherally-acting, mu-opioid receptor antagonist (PAMORA), which has
been studied in opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, a common side
effect of prescription opioid pain medicines.
AstraZeneca has been informed that the US FDA Anesthetic and Analgesic Drug Products Advisory Committee
(AADPAC) is planning to review safety data as it relates to the PAMORA class of therapies for the treatment of
OIC. Naloxegol will be included as part of the FDA AADPAC discussion, at a date still to be determined.
Naloxegol is part of an exclusive worldwide license agreement between AstraZeneca and Nektar Therapeutics.
You're proud of that? don't be .. still only 2.00 pre split. been dead money for years.